The present study aimed to analyze the expression and effects of NUAK2 in gastric cancer and adjacent normal gastric tissues. The protein expression levels of NUAK2 were detected by western blot analysis. The effects of NUAK2 expression on the proliferation of gastric cancer cells was detected using an MTT and BrdU incorporation assay. Furthermore, the effects of NUAK2 on proliferation and cancer stem cell markers, both protein and microRNA (miRNA), were investigated by western blot analysis and miRNA microarrays, respectively. The results demonstrated that NUAK2 was able to significantly promote the proliferation of SGC-7901 gastric cancer cells. In addition, NUAK2 overexpression decreased the percentage of cells in the G1 phase and increased the percentage of cells in the S phase. Western blot analysis and miRNA microarrays revealed that overexpression of NUAK2 resulted in increased expression levels of proliferation markers, including c-myc, proliferating cell nuclear antigen, cyclin-dependent kinase 2, miRNA 21, and gastric cancer stem cell markers, including aldehyde dehydrogenase 1, CD44 and CD133. In conclusion, NUAK2 expression differed between the tumor and normal gastric tissues. NUAK2 was able to promote the proliferation of gastric cancer cells and regulate their cell cycle. Proliferation and cancer stem cell markers were upregulated by NUAK2 expression. Therefore, the results from the present study suggest that NUAK2 may be a promising target for gastric cancer therapy in the future.
Introduction
Gastric cancer is a common malignant tumor with a high mortality rate in Asian countries (1) . The molecular pathogenesis of gastric cancer is complex and remains poorly understood; however, several factors are reported to be important in promoting gastric cancer (2, 3) , including oncogene protein expression (4) . These proteins have varying expression levels in tumor and normal gastric tissues, and are able to cause a variety of changes in the biological behavior of cells (5) .
NUAK2 is an important gene that regulates cell cycle progression and cell migration in melanoma cells (6) . The importance of NUAK2 in melanomagenesis is highlighted by its impact on the survival of patients with acral melanomas (7) . In addition, NUAK2 participates in the regulation of cell proliferation of melanomas (8) . A previous study demonstrated that NUAK2 and the phosphoinositide 3-kinase (PI3K) signaling pathway control the expression of cyclin-dependent kinase 2 (CDK2), increase the S-phase population in the cell cycle profile and increase the proliferation of both C32 and SM2-1 melanoma cells (9) . However, the expression and function of NUAK2 in gastric cancer has yet to be elucidated.
In the present study, the expression of NUAK2 in gastric cancer was investigated. In addition, an SGC-7901 cell model overexpressing NUAK2 was used to investigate the possible mechanisms underlying the effects of NUAK2 on gastric cancer.
Materials and methods
Tumor specimens and cell culture. Gastric cancer tissue specimens were collected from eight patients (age, 50-60 years; 3 female, 5 male) at the Shanghai Jiao Tong University Affiliated Sixth People's Hospital (Shanghai, China) from January 2011 to December 2014. Matched non-tumor adjacent tissue was obtained from a segment of the resected specimens that was the farthest from the tumor (>5 cm). Diagnosis of gastric cancer were based on histopathological evaluation. Written informed consent was obtained from the patients and the study was approved by the Medical Ethics Committees of the Shanghai Jiao Tong University Affiliated Sixth People's Hospital. The SGC-7901 gastric cancer cell line (MD Anderson Cancer Center, Houston, TX, USA) was cultured and maintained as previously described (10 After blocking 5% non-fat dry milk in TBS, the membranes were then incubated with the following primary antibodies overnight at 4˚C: Anti-NUAK2 (cat. no. ab107287), anti-c-myc (cat. no. ab32072), anti-p21 (cat. no. ab47452), anti-p53 (cat. no. ab131442), anti-proliferating cell nuclear antigen (PCNA; cat. no. ab18197), anti-CDK2 (cat. no. ab70012), anti-aldehyde dehydrogenase 1 (ALDH1; cat. no. ab190298), anti-CD44 (cat. no. ab157107), anti-β-actin (cat. no. ab8226) (all purchased from Abcam, Cambridge, MA, USA and used at a 1:500 dilution) and anti-CD133 (11) (supplied by Tongji Medical College Huazhong University of Science and Technology, Shanghai, China). Incubation with horseradish peroxidase-conjugated anti-mouse (cat. no. sc-2375) and anti-rabbit (cat. no. sc-2385) secondary antibodies (Santa Cruz Biotechnology, Inc., Dallas, TX, USA) was performed for 40 min at room temperature and enhanced chemiluminescence visualizations were performed as previously described (12) .
Vectors and transfection. NUAK2-expressing plasmids and empty vector (pcDNA3.1; provided by Tongji Medical College Huazhong University of Science and Technology) were used. For transfection experiments, the cells were cultured in serum-free medium without antibiotics at 60% confluence for 24 h, and then transfected with transfection reagent (Lipofectamine 2000; Invitrogen, Carlsbad, CA, USA) according to manufacturer's instructions. After incubation for 6 h, the medium was removed and replaced with normal culture medium for 48 h (13) .
Cell proliferation and cell-cycle assays. The viability of SGC-7901 cells was assessed using an MTT assay (Sigma-Aldrich, St. Louis, MO, USA). SGC-7901 cells were transfected with NUAK2 or pcDNA3.1 (mock). These cells were incubated in a humidified atmosphere with 5% CO 2 . Then, MTT solution (4.14 mg/ml) was added to each well and the optical density was measured after incubation at 37˚C for 4 h (14). Absorbance was directly proportional to the number of surviving cells. For the BrdU incorporation assays, a cell proliferation ELISA (Beyotime Institutes of Biotechnology, Inc., Shanghai, China) was used to analyze the incorporation of BrdU during DNA synthesis, following the manufacturer's instructions. Cell cycle profile analyses were performed as previously described (12) . Cells (8.0x10 5 ) were seeded into a 100-mm culture plate and allowed to attach overnight. The cells were transfected with plasmids for 24 h, washed twice with NaCl/Pi, and then centrifuged at 200 x g at room temperature. The pellet was resuspended in 1 ml cold NaCl/Pi and fxed in 70% ethanol for at least 12 h at 4˚C. The fixed cells were incubated with 100 µl DNase-free RNaseA (200 µg/ml) for 30 min at 37˚C, and then 1 mg/ml propidium iodide was added. The stained cells were analyzed using a fluorescence-activated cell sorter (BD Accuri C6; BD Biosciences, Ann Arbor, MI, USA). The percentages of cells in the G1, S and G2/M phases of the cell cycle were determined using CellQuest Pro software (FlowJo, Ashland, OR, USA).
RNA extraction and microRNA (miRNA) microarrays. Total RNA was extracted from the cells using TRIzol ® reagent (Invitrogen; Thermo Fisher Scientific, Inc.), in accordance with the manufacturer's instructions. miRNA microarrays were performed as previously described (12, 15) .
Statistical analysis. Data are presented as the mean ± standard deviation from at least three independent experiments. Differences between groups were analyzed using a Student's t-test. Statistical analyses were performed using SPSS 13.0 software (SPSS, Inc., Chicago, IL, USA). P<0.05 was considered to indicate a statistically significant difference.
Results

NUAK2 is upregulated in gastric cancer tissues.
To assess NUAK2 expression levels in gastric cancer, western blot analysis was conducted in eight pairs of gastric cancer tissue samples and matched adjacent normal tissue sample samples. The expression of NUAK2 was higher in the gastric cancer tissue samples compared with the normal tissue samples (Fig. 1) . These data indicate that NUAK2, which has an impact on the survival of patients with acral melanomas, may also act as an oncogene in gastric cancer.
NUAK2 overexpression promotes gastric cancer cell proliferation in vitro.
Since NUAK2 was observed to be upregulated in gastric cancer tissues, the effect of NUAK2 on gastric cancer proliferation was investigated. SGC-7901 cells were transfected with NUAK2-expressing plasmids or empty vector ( Fig. 2A) . The results demonstrated that cell proliferation was significantly increased in NUAK2-overexpressing cells compared with that of their corresponding controls, as determined by MTT and BrdU assays ( Fig. 2B and C) . Furthermore, NUAK2 overexpression decreased the percentage of cells in the G1 phase and increased the percentage of cells in the S phase (Fig. 2D) .
NUAK2 upregulates proliferation and cancer stem cell-associated protein expression.
To further explore the function of NUAK2 on tumor proliferation, western blotting was performed to identify whether proliferation markers were also affected by NUAK2 in the cells. The results demonstrated that c-myc, PCNA and CDK2 expression were upregulated, whereas p21 and p53 expression were downregulated by NUAK2 (Fig. 3) . In addition, western blotting was also performed to further confirm that NUAK2 was able to regulate cancer stem cell markers. The results demonstrated that the expression of gastric cancer stem cell markers ALDH1 (16), CD44 (17) and CD133 (18, 19) were upregulated in cells transfected with NUAK2-expressing plasmids compared with their corresponding controls (Fig. 3) . These data suggest that NUAK2 is able to promote the expression of proliferation and cancer stem cell markers in SGC-7901 cells.
NUAK2 upregulates proliferation-associated miRNA expression. Oncogenes or tumor suppressor genes may have 
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important roles in gastric cancer through the regulation of miRNAs (20, 21) . Having demonstrated that NUAK2, as an oncogene, promoted proliferation of SGC-7901 cells, it was hypothesized that NUAK2 was able to regulate proliferation-associated miRNA expression. In an attempt to identify that NUAK2 contributed to aberrant regulation of miRNA expression in SGC-7901 cells, miRNA profiling was performed in SGC-7901 cells transfected with NUAK2-expressing plasmids or empty vector. RNAs isolated from the cells were hybridized to a custom miRNA microarray platform. Following three hybridization cycles, quantification, and normalization, the expression of 36 miRNAs was altered in the cells transfected with NUAK2-expressing plasmids. Notably, miRNA21, which confers cisplatin resistance in gastric cancer cells by regulating phosphatase and tensin homolog (22), was significantly upregulated following NUAK2 overexpression (Fig. 4) . 
Discussion
Previous studies have demonstrated that several oncogenes and tumor suppressor genes are dysregulated in gastric cancer tissues or cell lines, and they have been shown to be associated with gastric cancer progression and disease outcome (23) (24) (25) . The present study demonstrated that NUAK2 overexpression may promote cell proliferation and cell-cycle progression in SGC-7901 cells. In addition, NUAK2 overexpression was observed to upregulate cancer stem cell markers, both protein and miRNAs, in SGC-7901 cells. Therefore, NUAK2 may be considered as an oncogene in the development of gastric cancer. NUAK2 is an emerging oncogene that regulates cell cycle progression and cell migration in melanoma cells (6, 7) . A previous study also indicated that NUAK2 and the PI3K signaling pathway coordinately control CDK2 by abrogating the growth of cutaneous melanomas (9) . The results of the present study suggested that NUAK2 may also act as an oncogene in gastric cancer. However, its underlying mechanisms require further investigations.
The cell cycle machinery has a pivotal role in regulating cell proliferation and tumor growth of cancer cells. A previous study demonstrated that NUAK2 regulates CDKs in melanoma cells (9) . Concordant with these results, the present study demonstrated that NUAK2 overexpression upregulates CDK2 and PCNA expression levels in gastric cancer cells. Previous studies have suggested that tumors develop because of a rare subpopulation of cells, known as cancer stem cells (CSCs), within a tumor (26, 27) . CSCs have been identified in numerous solid tumors and they have been shown to be promising for the development of anticancer drugs that are able to target all CSC subsets within a tumor to prevent recurrence (28, 29) . The results of the current study also demonstrated that NUAK2 was able to regulate CSC-associated markers, proteins and miRNAs, indicating it may have an essential role in tumor development.
In conclusion, the present study provides a novel role for NUAK2 in gastric cancer cell proliferation and regulation. These results suggest that NUAK2 may be a promising therapeutic target for gastric cancer therapy.
